ImExHS (ASX:IME) Shares Gain Following New ARR Contract in Zacatecas

Aditi Sarkar

25 May 2026 11:54 AM AEST

ImExHS (ASX:IME) Shares Gain Following New ARR Contract in Zacatecas

Image Source: shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

ImExHS secured a public tender contract covering 20 hospitals and clinics in Mexico
The contract adds approximately $384,000 in annual Recurring Revenue
The agreement also includes a one-time implementation fee of $50,000
Deployment includes AI workflow agents and diagnostic algorithms
Full annual recurring revenue contribution is expected from September 2026

ImExHS (ASX: IME) shares rose 5.56% to AUD 0.38 on 25 May after the healthcare imaging technology company announced it had secured a public tender contract for the deployment of its Aquila+ platform across 20 hospitals and clinics in Zacatecas, Mexico.

The agreement contributes approximately $384,000 in annual recurring revenue (ARR) alongside a one-time implementation fee of $50,000. Investors appeared to respond positively to the contract win, which further expands the company’s presence in the Latin American healthcare market and strengthens its public sector footprint.

The contract was secured through distributor partner GOBA and forms part of the company’s broader Mexico expansion strategy.

Aquila+ Deployment to Cover 20 Hospital Sites

According to the company, the deployment will span 20 public hospital locations and incorporate IMEXHS’s proprietary AI workflow agents embedded across the Aquila+ radiology platform. The implementation will also include two artificial intelligence diagnostic algorithms developed by Gleamer, specifically ChestView and Fracture Detection.

Management described the deployment as one of the more comprehensive AI-integrated radiology implementations undertaken within a public hospital network. The company stated that the combination of workflow automation and embedded diagnostic AI is designed to support imaging efficiency and clinical processes across healthcare systems.

Implementation activities have already commenced and are expected to be completed across all sites by the end of June 2026.

ARR Growth Remains a Key Investor Focus

Recurring revenue growth continues to be an important metric for software and healthcare technology companies, particularly those operating under subscription or platform-based Business models. ImExHS stated that the contract is expected to contribute a full ARR run rate from September 2026.

The addition of recurring revenue may be viewed positively by investors monitoring the company’s ability to scale its software platform across healthcare networks. Public healthcare contracts can also provide visibility over future revenue streams and strengthen relationships within institutional healthcare systems.

At the same time, execution remains important as the company progresses implementation across multiple hospital sites within a relatively short timeframe.

Mexico Expansion Strategy Gains Momentum

The latest contract reinforces ImExHS’s expansion strategy in Mexico, where the company continues pursuing opportunities in both private and public healthcare systems. Management stated that the contract demonstrates the company’s ability to compete successfully in government procurement processes.

Latin America remains an important market for healthcare imaging and digital health providers as healthcare systems continue modernising diagnostic infrastructure and adopting AI-supported technologies. Companies operating in the sector are increasingly seeking partnerships with healthcare providers to improve workflow efficiency, imaging analysis, and patient management systems.

ImExHS’s Partnership model with regional distributors such as GOBA may also support broader market access within the region.

AI Integration Continues to Shape Healthcare Imaging

Artificial intelligence adoption within radiology and diagnostic imaging has become an increasingly important trend across global healthcare systems. AI tools are being used to assist clinicians with imaging interpretation, workflow management, triage, and operational efficiency.

The integration of AI workflow agents and diagnostic algorithms within healthcare platforms reflects broader industry efforts to automate administrative tasks while supporting clinical decision-making. Hospitals and healthcare providers are also seeking technologies that can improve productivity and reduce reporting delays amid workforce pressures.

However, adoption timelines for healthcare AI technologies can vary depending on regulatory requirements, integration complexity, procurement cycles, and healthcare funding conditions.

About the Company

ImExHS (ASX: IME) is a healthcare imaging technology company focused on radiology software, imaging storage, and artificial intelligence solutions for healthcare providers. The company’s Aquila+ platform supports diagnostic imaging workflows and is used across healthcare systems in Latin America and other international markets. ImExHS continues expanding its AI-enabled healthcare technology offerings through partnerships and platform deployments.

Industry Trends and Market Context

The global healthcare technology sector continues to experience growing Demand for digital imaging, cloud-based radiology systems, and AI-supported diagnostic tools. Healthcare providers are increasingly investing in technologies designed to improve operational efficiency, reduce reporting backlogs, and enhance patient care outcomes.

Artificial intelligence integration within radiology remains a rapidly evolving segment, with software companies competing to provide scalable workflow and diagnostic solutions for hospitals and healthcare networks. Public healthcare procurement opportunities are also becoming increasingly important for technology providers seeking long-term recurring revenue growth.

At the same time, healthcare technology companies face challenges related to implementation complexity, Cybersecurity requirements, regulatory compliance, and integration with existing hospital systems. Adoption cycles in public healthcare environments can also be lengthy and subject to budget constraints.

Bullish Perspective

Supporters of ImExHS may view the Mexico contract as evidence of growing demand for the company’s AI-integrated radiology platform. The increase in recurring revenue and expansion into public healthcare systems may also support confidence in the company’s long-term scaling strategy.

Investors may additionally focus on broader growth trends in healthcare AI adoption and digital imaging infrastructure, particularly across emerging healthcare markets.

Bearish Perspective

More cautious investors may note that healthcare technology deployments can involve execution risks, implementation delays, and integration challenges across hospital networks. Revenue realisation timelines may also depend on successful deployment completion and customer retention.

Competition within healthcare imaging and AI software markets also remains elevated, with larger global technology providers and specialised healthcare software companies competing for institutional contracts.

Investment Risks and Challenges

ImExHS operates in a competitive healthcare technology sector where product innovation, platform reliability, and implementation execution are critical. Delays in deployment or integration challenges could affect customer satisfaction and revenue timing.

The company may also face risks related to regulatory compliance, cybersecurity, healthcare procurement cycles, and changing government healthcare budgets. Dependence on international expansion and distributor partnerships may introduce additional operational complexity.

Currency fluctuations, technology adoption trends, and competitive pressures within AI-driven healthcare software markets may also influence future financial performance and investor sentiment.

FAQs

Q: Why did ImExHS shares rise on 25 May?

A: ImExHS shares gained after the company announced a public tender contract in Mexico covering the deployment of its Aquila+ platform across 20 hospitals and clinics.

Q: How much recurring revenue will the Mexico contract add?

A: The contract is expected to contribute approximately

Q: What technologies are included in the Aquila+ deployment?

A: The deployment includes IMEXHS’s AI workflow agents and Gleamer’s diagnostic algorithms, including ChestView and Fracture Detection.

Q: What are the key risks facing ImExHS?

A: Key risks include implementation delays, healthcare procurement complexity, competitive market pressures, regulatory compliance requirements, and technology integration challenges.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.